Core Viewpoint - The company, Green Biological Technology Co., Ltd., has submitted its IPO application for the third time, significantly increasing its fundraising target to 690 million yuan, up 84% from the previous 375 million yuan, despite ongoing issues such as declining capacity utilization, insufficient R&D investment, and reliance on overseas markets [1][4]. Group 1: IPO Application and Fundraising - Green Biological's third IPO attempt comes after two previous withdrawals, with the latest application submitted on November 21, 2025, aiming to raise approximately 690 million yuan [4][10]. - The funds will be allocated to projects including a 6,300-ton high-grade spice production project, factory facility upgrades, and R&D innovation projects [5][6]. Group 2: Operational Challenges - The company has faced compliance issues, including environmental violations leading to administrative penalties totaling over 1 million yuan, which have raised regulatory concerns [3][4]. - Capacity utilization rates have been declining, with figures of 76.15%, 67.51%, 73.79%, and 53.87% from 2022 to the first half of 2025, indicating underutilization of existing production capacity [6][7]. Group 3: R&D Investment - R&D investment has been a point of contention, with a total of 59.45 million yuan spent over the last three years, and R&D expense ratios barely meeting the minimum threshold for high-tech enterprises [8][10]. - The structure of R&D spending shows a significant increase in personnel costs, which rose by 109% in 2024, raising concerns about the company's commitment to genuine innovation [8][9]. Group 4: Financial Performance - Despite operational challenges, the company has reported impressive revenue and net profit growth rates of 23.35% and 48.59% respectively over the past three years, which supports its renewed IPO efforts [10][11]. - The company's total assets have increased from 1.19 billion yuan in 2022 to 1.75 billion yuan in the first half of 2025, while the debt-to-asset ratio has remained high, averaging around 62% [11][17]. Group 5: Governance and Control - The transition of control from founder Lu Wenchong to his daughter Lu Wei has raised governance concerns, particularly regarding the concentration of power within the family [12][15]. - The family now controls 36.11% of the shares, with management holding over 57%, which may lead to a lack of external checks and balances in decision-making [12][15]. Group 6: Market Dependency - The company heavily relies on overseas markets, with export revenues constituting approximately 85% of total sales, which poses risks if market conditions change [20][21]. - Customer concentration is also high, with the top five clients accounting for around 43.98% to 42.30% of sales from 2022 to the first half of 2025, indicating vulnerability to shifts in these key relationships [21][22].

Core Viewpoint - The company, Green Biotechnology Co., Ltd., has submitted its prospectus to the Shenzhen Stock Exchange's ChiNext, aiming to raise approximately 690 million yuan. This marks the company's third attempt at an IPO, following two previous withdrawals due to issues related to environmental disclosures, performance fluctuations, and uncertainties regarding its ChiNext positioning. Despite showing growth in performance, the company faces significant uncertainties regarding its listing prospects due to high debt levels, weak R&D, insufficient capacity utilization, environmental compliance concerns, and issues related to excessive dividends [1][9]. Financial Performance - Green Biotechnology has shown a growth trend in revenue and net profit in recent years. From 2022 to 2024, the company's revenue is projected to increase from 631 million yuan to 961 million yuan, with a compound annual growth rate (CAGR) of 23.35%. The net profit attributable to shareholders is expected to rise from 68.14 million yuan to 150 million yuan, with a CAGR of 48.59%. In the first half of 2025, revenue reached 548 million yuan, and net profit was 94.58 million yuan, maintaining a high level [2][10]. R&D Investment Concerns - The company's R&D investment intensity is significantly below industry standards. From 2022 to 2024, the R&D expenditure as a percentage of revenue was 2.34%, 2.52%, and 2.73%, respectively, consistently falling short of the 3% threshold required for high-tech enterprises. In contrast, comparable companies had average R&D expenditure ratios of 4.31%, 4.59%, and 4.28% during the same period. Notably, the structure of R&D investment showed abnormal fluctuations, with personnel costs surging by 109% in 2024, raising concerns about potential "window dressing" to meet IPO standards [3][11]. Debt and Liquidity Issues - As of June 30, 2025, the company's debt-to-asset ratio stood at 62.13%, significantly higher than the highest ratio of 41.2% among comparable companies. The total interest-bearing debt increased from 600 million yuan at the end of 2022 to 891 million yuan by mid-2025, a rise of 48.5%. The company faced a liquidity gap of 244 million yuan, with cash and cash equivalents amounting to only 95.96 million yuan [5][13]. Dividend Policy - Despite high debt levels and liquidity constraints, the company distributed substantial cash dividends totaling 160 million yuan from 2022 to 2024, representing 51.36% of the cumulative net profit of approximately 311 million yuan during the same period. This raises questions about the rationale behind prioritizing dividends over retaining earnings to address liquidity issues [6][14]. Capacity Utilization and Expansion Plans - The company's capacity utilization rates have been declining, with the main production facility's utilization dropping from 76.15% in 2022 to 53.87% in the first half of 2025. Despite this, the company plans to invest 420 million yuan in a new project to increase production capacity by over 50%, which raises concerns about the necessity and effectiveness of such expansion given the current overcapacity [7][15]. Environmental Compliance Issues - The company has faced multiple administrative penalties, particularly related to environmental compliance, with five out of seven penalties directly linked to environmental issues. The major project for which the company seeks funding is still awaiting environmental approval, posing risks of delays or project cancellations. Previous IPO attempts were hindered by undisclosed environmental penalties, indicating ongoing compliance challenges [8][16].